Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Enfortumab Vedotin for the Treatment of Patients with Recurrent and/or Metastatic Adenoid Cystic Carcinoma

Trial Status: active

This phase II trial tests how well enfortumab vedotin works in treating patients with adenoid cystic carcinoma (salivary gland cancer) that has come back after a period of improvement (recurrent) and/or has spread from where it first started (primary site) to other places in the body (metastatic). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of cancer cells. Enfortumab attaches to a protein called nectin-4 on cancer cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Giving enfortumab vedotin may work better in treating patients with recurrent and/or metastatic adenoid cystic carcinoma.